Literature DB >> 28177543

Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon.

Aisha Elsharkawy1, Shereen Abdel Alem1, Rabab Fouad1, Maissa El Raziky1, Wafaa El Akel1, Mahmoud Abdo1, Omnia Tantawi1, Mohamed AbdAllah2, Marc Bourliere3, Gamal Esmat1.   

Abstract

BACKGROUND AND AIM: Accurate evaluation of the degree of liver fibrosis in patients with chronic liver diseases is crucial, as liver fibrosis is important in order to make therapeutic decisions, determine prognosis of liver disease and to follow-up disease progression. Multiple non-invasive methods have been used successfully in the prediction of fibrosis; however, early changes in non-invasive biomarkers of hepatic fibrosis under effective antiviral therapy are widely unknown. The aim of this study is to evaluate changes of transient elastography values as well as FIB-4 and AST to platelet ratio index (APRI) in patients treated with Sofosbuvir-based treatment regimen.
METHODS: This is a retrospective study including 337 chronic HCV Egyptian patients with genotype 4 mainly. They were treated with Sofosbuvir-based treatment regimen. Transient elastography values were recorded as well as FIB-4 and APRI were calculated at baseline and SVR12.
RESULTS: There was a significant improvement of platelets counts, ALT and AST levels, which in turn cause significant improvement in FIB-4 and APRI scores at SVR12. Liver stiffness measurements were significantly lower in SVR12 (14.8 ± 10.7 vs 11.8 ± 8.8 kPa, P = 0.000). About 77% of responders and 81.1% of cirrhotic patients showed improvement in liver stiffness measurements at SVR12.Univariate and multivariate regression analysis showed that failure to achieve improvement in liver stiffness measurements were significantly associated with relapsers and low baseline liver stiffness measurement.
CONCLUSION: Sofosbuvir-based treatment resulted in a clinically significant improvement in parameters of liver fibrosis.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Sofosbuvir-based treatment; chronic hepatitis C virus; fibrosis scores; transient elastography

Mesh:

Substances:

Year:  2017        PMID: 28177543     DOI: 10.1111/jgh.13758

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  23 in total

1.  Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience.

Authors:  Luca Rinaldi; Maria Guarino; Alessandro Perrella; Pia Clara Pafundi; Giovanna Valente; Luca Fontanella; Riccardo Nevola; Barbara Guerrera; Natalina Iuliano; Michele Imparato; Alessio Trabucco; Ferdinando Carlo Sasso; Filomena Morisco; Antonio Ascione; Guido Piai; Luigi Elio Adinolfi
Journal:  Dig Dis Sci       Date:  2019-04-01       Impact factor: 3.199

Review 2.  Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions.

Authors:  Paul Kennedy; Mathilde Wagner; Laurent Castéra; Cheng William Hong; Curtis L Johnson; Claude B Sirlin; Bachir Taouli
Journal:  Radiology       Date:  2018-03       Impact factor: 11.105

3.  Imaging biomarkers of diffuse liver disease: current status.

Authors:  Bachir Taouli; Filipe Caseiro Alves
Journal:  Abdom Radiol (NY)       Date:  2020-06-25

4.  Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis C patients.

Authors:  Anya Mezina; Arunkumar Krishnan; Tinsay A Woreta; Kevin B Rubenstein; Eric Watson; Po-Hung Chen; Carla Rodriguez-Watson
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534

Review 5.  Fibrosis regression following hepatitis C antiviral therapy.

Authors:  Aisha Elsharkawy; Reham Samir; Mohamed El-Kassas
Journal:  World J Hepatol       Date:  2022-06-27

6.  Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy.

Authors:  Mohamed Ahmed Samy Kohla; Ahmed El Fayoumi; Mohamed Akl; Mervat Abdelkareem; Mahmoud Elsakhawy; Sally Waheed; Mai Abozeid
Journal:  Clin Exp Med       Date:  2019-12-02       Impact factor: 3.984

7.  Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.

Authors:  Kiminori Kimura; Akemi Ikoma; Maki Shibakawa; Shinji Shimoda; Kenichi Harada; Masanao Saio; Jun Imamura; Yosuke Osawa; Masamichi Kimura; Koji Nishikawa; Takuji Okusaka; Satoshi Morita; Kazuaki Inoue; Tatsuya Kanto; Koji Todaka; Yoichi Nakanishi; Michinori Kohara; Masashi Mizokami
Journal:  EBioMedicine       Date:  2017-08-19       Impact factor: 8.143

Review 8.  PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy.

Authors:  Dave P Nichols; Scott H Donaldson; Carla A Frederick; Steven D Freedman; Daniel Gelfond; Lucas R Hoffman; Andrea Kelly; Michael R Narkewicz; Jessica E Pittman; Felix Ratjen; Scott D Sagel; Margaret Rosenfeld; Sarah Jane Schwarzenberg; Pradeep K Singh; George M Solomon; Michael S Stalvey; Shannon Kirby; Jill M VanDalfsen; John P Clancy; Steven M Rowe
Journal:  J Cyst Fibros       Date:  2021-02-19       Impact factor: 5.482

9.  Liver cT1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus.

Authors:  Eleanor Barnes; Michael Pavlides; Arjun N A Jayaswal; Christina Levick; Jane Collier; Elizabeth M Tunnicliffe; Matthew D Kelly; Stefan Neubauer
Journal:  Abdom Radiol (NY)       Date:  2020-11-28

10.  Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals.

Authors:  Veronika Pietsch; Katja Deterding; Dina Attia; Kristina Imeen Ringe; Benjamin Heidrich; Markus Cornberg; Michael Gebel; Michael Peter Manns; Heiner Wedemeyer; Andrej Potthoff
Journal:  United European Gastroenterol J       Date:  2018-06-27       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.